Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests following the exercise of options through his controlled entity Union Square Capital Pty Ltd. The transaction saw the conversion of 312,500 options into ordinary shares and the disposal of an equivalent number of 1AIO options, modestly increasing his indirect shareholding while simplifying his mix of derivative securities.
After the change, Hainsworth’s indirect holding rose to 5,937,500 ordinary shares, alongside existing unlisted options, while his substantial direct holdings of shares, performance rights and options remained unchanged. The move signals continued equity alignment between the director and shareholders, but does not alter the company’s broader capital structure or indicate any change in strategic direction.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australia-listed biotechnology company focused on developing pharmaceutical products. The company operates in the life sciences sector, with its securities traded on the ASX and its capital structure including ordinary shares, performance rights and various classes of options held by directors and other investors.
YTD Price Performance: 14.29%
Average Trading Volume: 1,541,148
Technical Sentiment Signal: Hold
Current Market Cap: A$25.62M
For detailed information about 1AI stock, go to TipRanks’ Stock Analysis page.